FluoGuide AS
96X
Company Profile
Business description
FluoGuide AS is a clinical-stage biotechnology company focused on developing drugs that maximize surgical outcomes by making cancer fluorescent. Its technology includes uPAR, which is part of a proteolytic system, and FG001, a product injected into the patient's vein prior to surgery.
Contact
Titanhus, Titangade 9-13
CopenhagenDK-2200
DNKT: +45 31226660
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
8
Stocks News & Analysis
stocks
After earnings, is Amazon stock a buy, a sell, or fairly valued?
With temperature on tariffs easing and a raised fair value estimate, here’s what we think of Amazon’s results.
stocks
National Australia Bank earnings: Standing ground in business lending, but no earnings growth
Our view of the prospects for NAB shares.
stocks
Progress in UK expansion for undervalued ASX share
Guidance reaffirmed and UK implementation on track.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,061.90 | 15.00 | -0.17% |
| CAC 40 | 7,950.18 | 124.05 | -1.54% |
| DAX 40 | 23,569.96 | 164.06 | -0.69% |
| Dow JONES (US) | 46,987.10 | 323.90 | -0.68% |
| FTSE 100 | 9,646.00 | 89.78 | -0.92% |
| HKSE | 26,241.83 | 244.07 | -0.92% |
| NASDAQ | 23,004.54 | 495.26 | -2.11% |
| Nikkei 225 | 50,613.19 | 270.49 | -0.53% |
| NZX 50 Index | 13,533.65 | 43.16 | -0.32% |
| S&P 500 | 6,728.80 | 8.48 | 0.13% |
| S&P/ASX 200 | 8,790.30 | 20.20 | -0.23% |
| SSE Composite Index | 3,997.56 | 10.20 | -0.25% |